Rhodamined TLR2 Pep-Orid-Liposome Efficiently Accumulated and Retained In Vivo To explore the bio-distribution of TLR2 pep-conjugated drug, we prepared rhodamine-labeled orid-liposome and TLR2 pep-orid-liposome
The downside of this is that there are no half-doses or slow adjustments, and you get the manufacturers standard treatment
doi: Lee J, Kwon A, Chae HW, Lee WJ, Kim TH, Kim HS
In addition, among other substances, several peptides have been added to Category 2 because FDA has identified significant safety risks with [those] substances, the agency said
Thats exactly what well unpack in this upcoming conversation: Before You Cover GLP-1s: The Step-Back, Step-Down Strategy for Employers March 3 Markyia Nichols, M.D., Chief Medical Officer, Ciba Health Well cover: What often gets overlooked when prescriptions come first How addressing root causes earlier can reduce long-term reliance on GLP-1s What a responsible, clinically sound step-down strategy actually looks like How to think about the lifetime cost of GLP-1 use, and why a structured off-ramp matters